| Cash Flow | 2025-09-30 | 2025-06-30 |
|---|---|---|
| Net cash provided by financing activities | 800 | 1,330 |
| Effect of foreign exchange rate on cash, cash equivalents and restricted cash | 18 | 20 |
| Net increase in cash, cash equivalents and restricted cash | 12,926 | 23,649 |
| Cash and cash equivalents at beginning of period | 17,456 | - |
| Cash and cash equivalents at end of period | 30,382 | - |
RxSight, Inc. (RXST)
RxSight, Inc. (RXST)